Cidofovir may be deleterious in BK virus-associated nephropathy

Transplantation

Volumn 89, Issue 12, 2010, Pages 1542-1544

  Pallet, Nicolas ^a   Burgard, Marianne ^a   Quamouss, Ouadie ^a   Rabant, Marion ^a   Bererhi, Lynda ^a   Martinez, Frank ^a   Thervet, Eric ^a   Anglicheau, Dany ^a   Noel, Laure Hélène ^a   Rouzioux, Christine ^a   Legendre, Christophe ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

BK VIRUS; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY INFECTION; KIDNEY TRANSPLANTATION; LETTER; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; VIREMIA; VIRUS INFECTION;

ANTIVIRAL AGENTS; BK VIRUS; CYTOSINE; GRAFT SURVIVAL; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; PHOSPHONIC ACIDS; POLYOMAVIRUS INFECTIONS; TREATMENT OUTCOME; TUMOR VIRUS INFECTIONS;

EID: 77954083114     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181d7212f     Document Type: Letter

References (23)

1. Agha I, Brennan DC. BK virus and immuno-suppressive agents. Adv Exp Med Biol 2006; 577: 174.
2. Binggeli S, Egli A, Dickenmann M, et al. BKV replication and cellular immune responses in renal transplant recipients. Am J Transplant 2006; 6: 2218.
3. Ramos E, Hirsch HH. Polyomavirus-associated nephropathy: Updates on a persisting challenge. Transpl Infect Dis 2006; 8: 59.
4. Bohl DL, Brennan DC. BK virus nephropa-thy and kidney transplantation. Clin J Am Soc Nephrol 2007; 2(suppl 1): S36.
5. Dall A, Hariharan S. BK virus nephritis after renal transplantation. Clin J Am Soc Nephrol 2008; 3(suppl 2): S68.
6. Drachenberg CB, Hirsch HH, Papadimitriou JC, et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: A prospective evaluation. Transplantation 2007; 84: 323.
7. Drachenberg CB, Papadimitriou JC, Ramos E. Histologic versus molecular diagnosis of BK polyomavirus-associated nephropathy: A shifting paradigm? Clin J Am Soc Nephrol 2006; 1: 374.
8. Hirsch HH, Suthanthiran M. The natural history, risk factors and outcomes of polyomavi-rus BK-associated nephropathy after renal transplantation. Nat Clin Pract Nephrol 2006; 2: 240.
9. Ramos E, Drachenberg CB, Wali R, et al. The decade of polyomavirus BK-associated ne-phropathy: State of affairs. Transplantation 2009; 87: 621.
10. Babel N, Fendt J, Karaivanov S, et al. Sustained BK viruria as an early marker for the development of BKV-associated nephropa-thy: Analysis of 4128 urine and serum samples. Transplantation 2009; 88: 89.
11. Li YJ, Chen YC, Lai PC, et al. A direct association of polyomavirus BK viruria with deterioration of renal allograft function in renal transplant patients. Clin Transplant 2009; 23: 505.
12. Wu JK, Harris MT. Use of leflunomide in the treatment of polyomavirus BK-associated ne-phropathy. Ann Pharmacother 2008; 42: 1679.
13. Blanckaert K, De Vriese AS. Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients. Nephrol Dial Transplant 2006; 21: 3364.
14. Faguer S, Hirsch HH, Kamar N, et al. Leflunomide treatment for polyoma-virus BK-associated nephropathy after kidney transplantation. Transpl Int 2007; 20: 962.
15. Hirsch HH, Drachenberg CB, Steiger J, et al. Polyomavirus-associated nephropathy in renal transplantation: Critical issues of screening and management. Adv Exp Med Biol 2006; 577: 160.
16. Rinaldo CH, Hirsch HH. Antivirals for the treatment of polyomavirus BK replication. Expert Rev Anti Infect Ther 2007; 5: 105.
17. Saad ER, Bresnahan BA, Cohen EP, et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation 2008; 85: 850.
18. Trofe J, Hirsch HH, Ramos E. Polyomavirus-associated nephropathy: Update of clinical management in kidney transplant patients. Transpl Infect Dis 2006; 8: 76.
19. Araya CE, Lew JF, Fennell RS, et al. Intermediate dose cidofovir does not cause additive nephrotoxicity in BK virus allograft nephropathy. Pediatr Transplant 2008; 12: 790.
20. Costa C, Bergallo M, Astegiano S, et al. Monitoring of BK virus replication in the first year following renal transplantation.Nephrol Dial Transplant 2008; 23: 3333.
21. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allo-graft pathology. Kidney Int 1999; 55: 713.
22. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.
23. Randhawa P, Brennan DC. BK virus infection in transplant recipients: An overview and update. Am J Transplant 2006; 6: 2000.